NCT01313065 - Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions

Solid Tumors

Interventions

DRUG

VX15/2503

Dose escalation will begin at low doses and will gradually increase in each future cohort. The current trial design provides for 7 study cohorts with a 20 mg/kg expansion phase.

Trial Locations (2)

78229

South Texas Accelerated Research Therapeutics, LLC, San Antonio

85258

Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale